

# Anna Kryzhanivska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1302735/publications.pdf>

Version: 2024-02-01

23  
papers

5,238  
citations

933447

10  
h-index

888059

17  
g-index

23  
all docs

23  
docs citations

23  
times ranked

6388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of nitric oxide in pathogenesis of tumor growth and its possible application in cancer treatment. <i>Experimental Oncology</i> , 2023, 41, 210-215.	0.1	24
2	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 762-771.	1.6	71
3	Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	10.7	356
4	CHEMOTHERAPY IN RECTAL CANCER. <i>Wiadomości Lekarskie</i> , 2021, 74, 1816-1823.	0.3	1
5	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 327-327.	1.6	8
6	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4500-4500.	1.6	75
7	724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC). <i>Annals of Oncology</i> , 2021, 32, S727.	1.2	3
8	SURVIVAL OF PATIENTS WITH RECTAL CANCER. <i>Wiadomości Lekarskie</i> , 2021, 74, 2044-2051.	0.3	1
9	956...Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: results from the POD1UM-101 study. , 2021, 9, A1006-A1006.		3
10	ENHANCING HEALTHCARE THROUGH THE DEVELOPMENT OF MANAGERIAL COMPETENCIES OF THE HEALTHCARE LEADERS. <i>Financial and Credit Activity Problems of Theory and Practice</i> , 2021, 5, 486-496.	0.7	1
11	CHEMOTHERAPY IN RECTAL CANCER. <i>Wiadomości Lekarskie</i> , 2021, 74, 1816-1823.	0.3	0
12	SURVIVAL OF PATIENTS WITH RECTAL CANCER. <i>Wiadomości Lekarskie</i> , 2021, 74, 2044-2051.	0.3	0
13	2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIa NSCLC. <i>Annals of Oncology</i> , 2021, 32, S1374.	1.2	27
14	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i> , The, 2020, 396, 1817-1828.	13.7	992
15	LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. <i>Annals of Oncology</i> , 2020, 31, S1164-S1165.	1.2	30
16	268...A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101). , 2020, ,		3
17	Durvalumab plus platinum+etoposide versus platinum+etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	13.7	1,274
18	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319

#	ARTICLE	IF	CITATIONS
19	Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. <i>Annals of Oncology</i> , 2019, 30, v877-v878.	1.2	37
20	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 543-543.	1.6	11
21	Morphometric Characteristics and Features of Metachronous Breast Cancer. <i>Arhiv Klinično Medicini</i> , 2019, 25, .	0.1	0
22	CLINICAL AND IMMUNOHISTOCHEMICAL FEATURES OF PRIMARY BREAST CANCER AND METACHRONOUS OVARIAN AND ENDOMETRIAL TUMORS. <i>Experimental Oncology</i> , 2018, 40, 124-127.	0.1	2
23	Independent Extracurricular Work as a Means of Improving Knowledge of Fifth Year Students of Medicine Faculty at the Department of Oncology. <i>Arhiv Klinično Medicini</i> , 2016, 22, E2016210.	0.1	0